Repeated rocuronium dose — Competitive Intelligence Brief

Repeated rocuronium dose (Repeated rocuronium dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocking agent. Area: Anesthesiology.

phase 3 Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor Anesthesiology Small molecule

Target snapshot

Repeated rocuronium dose (Repeated rocuronium dose) — University Hospital, Antwerp. Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Repeated rocuronium dose TARGET	Repeated rocuronium dose	University Hospital, Antwerp	phase 3	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Succinylcholine Chloride	SUXAMETHONIUM	Novartis	marketed	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
Rocuronium Injectable Solution	Rocuronium Injectable Solution	Federal University of São Paulo	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Extubation U	Extubation U	Seganest	marketed	Neuromuscular blocking agent	Nicotinic acetylcholine receptor
Galantamine-CR	Galantamine-CR	Massachusetts General Hospital	marketed	Cholinesterase inhibitor with nicotinic receptor allosteric modulator	Acetylcholinesterase; nicotinic acetylcholine receptors
Nicotine Mini-Lozenge for 11 Months	Nicotine Mini-Lozenge for 11 Months	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist; Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Rocuronium + sugammadex	Rocuronium + sugammadex	Brno University Hospital	marketed	Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex)	Nicotinic acetylcholine receptor at the neuromuscular junction (rocuronium); rocuronium molecule itself (sugammadex)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocking agent class)

1. University Hospital, Antwerp · 3 drugs in this class
2. Ain Shams University · 2 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
5. Federal University of São Paulo · 1 drug in this class
6. Korea University Guro Hospital · 1 drug in this class
7. Assistance Publique Hopitaux De Marseille · 1 drug in this class
8. Ostfold Hospital Trust · 1 drug in this class
9. St. Antonius Hospital · 1 drug in this class
10. CHU de Reims · 1 drug in this class